Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement

GENEVA (SEPT. 23, 2024) – Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY), a biopharmaceutical company, announced it will receive a $2 million milestone payment from SWK Funding LLC (SWK) this month. This follows the FDA approval of Zevra Therapeutics Inc.’s arimoclomol for Niemann-Pick Disease Type C treatment.

The payment is part of a royalty monetization agreement between Relief and SWK. Relief received an initial $5.75 million in August 2024 and is eligible for up to an additional $5.25 million contingent on specific milestones. The FDA’s approval of arimoclomol marks the first $2 million milestone. Relief could receive $3.25 million more if OLPRUVA’s quarterly net sales hit $1.5 million by the end of Q3 2025.